$enGene Holdings (ENGN.US)$ Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 results Favorable tolerability profile with no drug-related discontinuations Detalimogene's profile to date supports its potential as a foundational therapy for NMIBC enGene to host a conference call to discuss preliminary data today at 8:00 a.m. ET enGene Hold...
1
3
Report
Wins333
:
Thanks for the update, but market responses otherwise got be something hidden
The position indicator has been the most helpful the last week with so many CB(circuit breakers) happening. I have been able to enter and exit with profits of 300% this week. Last week my stocks I had been holding for a long time finally came thru and my accounts went up 300%. So since July 16th I am up 600% and not planning on stopping. My next high risk investment is$WeBuy Global (WBUY.US)$. They have until Monday to get their stock over a 1.00 or delisting procedur...
The appointment of Lee Giguere, an experienced public biotech legal executive, is expected to strongly support enGene's growth as the company advances the development of EG-70 in its ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer.
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
enGene Holdings Stock Forum
enGene Reports Q1 Results: Strong Cash Position Funds Global Trial Expansion
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 results
Favorable tolerability profile with no drug-related discontinuations
Detalimogene's profile to date supports its potential as a foundational therapy for NMIBC
enGene to host a conference call to discuss preliminary data today at 8:00 a.m. ET
enGene Hold...
$Aptevo Therapeutics (APVO.US)$
$enGene Holdings (ENGN.US)$
$Trxade Health (MEDS.US)$
My next high risk investment is $WeBuy Global (WBUY.US)$. They have until Monday to get their stock over a 1.00 or delisting procedur...
No comment yet